Well according to management they're trying to harmonise the two. I think one phase III trial in EU with primary endpoint of ICP or headache and secondary in PMD or some vision related is probably the most likely/ideal
Ann: Appendix 4E and Annual Report, page-72
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.260M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 68013 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8695 | 1 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable